Vol 10 - Jun 2025 Evidence for Primary Care
Evidence for Primary Care: the latest evidence from the Trip Database
A summary of some of the most important new documents for primary care that have recently been added to the Trip Database
Needles, Nerves, and Notifications: What’s Worth Your Time (and Wrist) in Modern Medicine?
This edition spotlights three of the buzziest topics in modern healthcare: GLP-1s for weight loss, vagus nerve stimulation for headaches, and smartwatches for spotting atrial fibrillation. But are they breakthroughs—or just buzz?
Let’s start with GLP-1 receptor agonists like semaglutide and tirzepatide. These injectable medications are effective for people with type 2 diabetes and those with obesity-related health risks—but only when prescribed responsibly. They’re not cosmetic tools, and buying them from questionable sources is a serious gamble. Reproductive health, surgery timing, and gastrointestinal side effects all need consideration.
Next, noninvasive vagus nerve stimulation (nVNS). It shows modest promise in preventing cluster headaches, but not migraines—and it’s not cheap. The evidence is low quality, yet some patients like the non-drug, noninvasive nature. If you’re looking for a high-tech solution and willing to roll the dice, it might be worth exploring—but with caution.
And then there’s the smartwatch. Surprisingly accurate at detecting atrial fibrillation in high-risk or asymptomatic people, it’s a potentially powerful screening tool. But until randomized trials are in, it’s best seen as a helpful adjunct—not a replacement—for traditional diagnostics like ECGs or Holter monitors.
The takeaway? These innovations all have potential, but they also need context, caution, and clinical oversight. GLP-1s are the most evidence-backed, smartwatches are promising but premature, and nVNS is still a bit of a long shot.
Innovation is exciting—but in medicine, good evidence still trumps good marketing.
Stay curious,
The Evidence Enthusiast
In This Edition
- Should GLP-1 Medicines Be Used for Weight Loss and Diabetes, and What Do Patients Need to Know?
- Is Noninvasive Vagus Nerve Stimulation (nVNS) Effective and Cost-Effective for Treating Cluster Headache and Migraine?
- Are smartwatches clinically and cost-effective for detecting atrial fibrillation?
- Does exercise training improve cognitive function in adults with depression?
- Which nonsurgical treatments are effective for adults with acute and subacute sciatica?
- How should headaches be diagnosed and managed in people over 12 years old?
- What are the long-term effects of lifestyle and metformin interventions on type 2 diabetes prevention over 21 years?
- How should primary care providers assess and manage chronic kidney disease in adults?
- Does adding simvastatin to escitalopram improve depressive symptoms in patients with major depression and obesity?
- What are the best practices for pain management during in-office uterine and cervical procedures?
- Are digital diabetes prevention programmes effective and cost-efficient in reducing the risk of type 2 diabetes in high-risk populations?
- Does taking antihypertensive medication at bedtime improve cardiovascular outcomes in frail older adults compared to morning dosing?
- Can standardised education and timely primary care transition improve long-term outcomes in patients with hypertensive disorders of pregnancy?
- Does adding parenting training to family-based behavioral treatment improve weight loss outcomes in children with obesity?
- Are oral hypoglycaemic drugs effective and safe as add-on therapy to insulin in patients with type 1 diabetes mellitus?
- How should primary-care clinicians in Canada diagnose and treat hypertension in adults, according to the 2025 Hypertension Canada guideline?
MHRA
Should GLP-1 Medicines Be Used for Weight Loss and Diabetes, and What Do Patients Need to Know?
Clinical Bottom Line: GLP-1 receptor agonists (GLP-1 RAs), including semaglutide, tirzepatide, and liraglutide, are effective and licensed treatments for type 2 diabetes and, in some cases, for weight management in people who are overweight or obese. They should only be used under medical supervision and for approved indications. Use outside of these contexts—especially for cosmetic weight loss—carries significant health risks, including the dangers of counterfeit products. Prescribers must also consider reproductive status, surgical timing, and potential gastrointestinal side effects.
Summary: GLP-1 receptor agonists, such as semaglutide, tirzepatide, and liraglutide, are prescription-only medicines used to treat type 2 diabetes and, in some cases, support weight loss in people who are obese or overweight with related health issues. They work by mimicking hormones that regulate appetite and blood sugar. These medicines should only be used under medical supervision and for approved purposes—not for cosmetic weight loss. They carry risks of side effects like nausea and, rarely, pancreatitis. They are not recommended during pregnancy or breastfeeding and may interfere with oral contraceptives. Buying them from unregulated sources poses serious health dangers, including counterfeit products.
View ArticleOntario HTA
Is Noninvasive Vagus Nerve Stimulation (nVNS) Effective and Cost-Effective for Treating Cluster Headache and Migraine?
Clinical Bottom Line: Noninvasive vagus nerve stimulation (nVNS) may offer modest benefits for some patients with cluster headache or migraine, particularly in preventing cluster headache, but the evidence is of low to very low quality. It is likely cost-effective for preventing cluster headache, but not for migraine due to high costs and limited effectiveness. Clinicians should weigh the uncertain benefits against the high public funding burden and consider patient preferences for noninvasive options.
Summary: This health technology assessment reviewed the clinical effectiveness, safety, cost-effectiveness, and patient perspectives on nVNS for cluster headache and migraine. Evidence showed that nVNS may modestly reduce attack frequency and improve response in cluster headache prevention, but benefits in migraine are smaller and uncertain. Cost-effectiveness is favorable for cluster headache prevention but not for migraine. Patients valued the noninvasive nature of nVNS but acknowledged mixed clinical outcomes.
View ArticleHealth Technology Wales
Are smartwatches clinically and cost-effective for detecting atrial fibrillation?
Clinical Bottom Line: Smartwatches show high diagnostic accuracy (sensitivity ~95%, specificity ~94%) for detecting atrial fibrillation (AF), based on observational evidence. However, there is currently no robust clinical trial data or UK-specific cost-effectiveness analysis to support their routine use over traditional diagnostic tools such as ECG or Holter monitors. Ongoing RCTs may provide clearer guidance in the near future. Until then, smartwatches may serve as a promising adjunct for AF detection, particularly in at-risk or asymptomatic populations, but cannot yet replace established diagnostic strategies.
Summary: Smartwatches may offer a promising way to detect AF, particularly in asymptomatic or high-risk individuals. Current evidence is largely observational, with good diagnostic accuracy but limited trial and cost-effectiveness data. More research, including ongoing RCTs, is needed to guide their clinical use.
View ArticleInt J Nurs Stud.
Does exercise training improve cognitive function in adults with depression?
Clinical Bottom Line: Exercise training leads to small but significant improvements in overall cognition and key cognitive subdomains (processing speed, attention, memory, executive function) in adults with depression. Optimal effects were seen with low-intensity, twice-weekly sessions lasting over 60 minutes for at least 10 weeks.
Summary: This systematic review and meta-analysis of 22 RCTs found that exercise improves cognitive function in adults with depression. Benefits were observed across multiple domains, especially with longer, low-intensity sessions done regularly. While publication bias is possible, the evidence supports exercise as a useful nonpharmacological intervention to enhance cognition in this population.
View ArticleJ Orthop Sports Phys Ther.
Which nonsurgical treatments are effective for adults with acute and subacute sciatica?
Clinical Bottom Line: Some nonsurgical treatments—including NSAIDs plus physical therapy, antidepressants, antibiotics, music therapy, and steroids—may improve leg pain and function in acute and subacute sciatica. However, all findings are based on very low-confidence evidence due to study limitations and imprecision.
Summary: This systematic review and network meta-analysis of 40 RCTs (5381 participants) found that several nonsurgical treatments may help reduce leg pain and improve function in adults with acute/subacute sciatica. Short-term benefits were seen with NSAIDs + physical therapy, antidepressants, and antibiotics (for pain), and music therapy (for function). Steroids showed benefits at longer follow-up. No treatments significantly increased adverse events. Due to very low-confidence evidence, results should be interpreted cautiously.
View ArticleNICE
How should headaches be diagnosed and managed in people over 12 years old?
Clinical Bottom Line: This NICE guideline provides evidence-based recommendations for the diagnosis and management of common primary headache disorders (migraine, tension-type, and cluster headaches), as well as medication overuse headache in people aged 12 and older. Key principles include avoiding unnecessary neuroimaging, using headache diaries for diagnosis and monitoring, optimizing acute and preventive treatments based on headache type, and identifying medication overuse early. Treatment should be tailored to individual needs, with consideration for age, comorbidities, pregnancy, and risk of adverse effects.
Summary: This NICE guideline outlines the diagnosis and management of common primary headaches—migraine, tension-type, cluster—and medication overuse headache in people aged 12 and over. It emphasises making a positive clinical diagnosis without unnecessary imaging, using headache diaries to support diagnosis and management, and tailoring treatment to the individual. Acute migraine treatment includes a triptan plus NSAID or paracetamol, while preventive options include propranolol, topiramate, or amitriptyline. Cluster headaches should be treated with oxygen or triptans, and verapamil may be used for prevention. Medication overuse headache is managed by withdrawing overused drugs and addressing the underlying primary headache.
View ArticleLancet Diabetes Endocrinol.
What are the long-term effects of lifestyle and metformin interventions on type 2 diabetes prevention over 21 years?
Clinical Bottom Line: In people with prediabetes, intensive lifestyle intervention and metformin both produced sustained reductions in type 2 diabetes incidence over 21 years, with lifestyle changes showing the greatest and longest-lasting benefit. Effects were most pronounced in those at higher baseline risk (for lifestyle intervention) and in younger individuals (for metformin), suggesting opportunities for targeted prevention strategies.
Summary: This 21-year follow-up of the Diabetes Prevention Program (DPP) and its continuation study (DPPOS) shows that early intensive lifestyle changes reduced type 2 diabetes incidence by 24% and metformin by 17% compared to placebo. While the strongest benefits occurred in the first 3 years, the advantages persisted long-term. Lifestyle intervention extended diabetes-free survival by 3.5 years, and metformin by 2.5 years. Effects varied by baseline risk: lifestyle worked best in those with higher fasting glucose or HbA1c, while metformin was more effective in younger adults. These findings support long-term preventive strategies and tailored interventions for high-risk groups.
View ArticleVeterans Affairs
How should primary care providers assess and manage chronic kidney disease in adults?
Clinical Bottom Line: The 2025 VA/DoD guideline provides evidence-based recommendations for the primary care management of chronic kidney disease (CKD), emphasizing early detection, risk stratification, and coordinated care. Routine testing with eGFR and urine albumin-to-creatinine ratio is recommended in high-risk groups. Pharmacologic interventions—especially ACE inhibitors/ARBs, SGLT2 inhibitors, and statins—are strongly supported for slowing disease progression and reducing cardiovascular risk. Risk prediction tools (e.g., KFRE) and shared decision-making are encouraged to individualize care and guide referrals. The guideline reflects evolving evidence and promotes proactive, team-based CKD management.
Summary: This comprehensive update to the VA/DoD guideline outlines best practices for identifying and managing CKD in adults within primary care settings. It recommends targeted testing using eGFR and UACR in patients with risk factors such as age >60, diabetes, hypertension, and cardiovascular disease. Combining creatinine and cystatin C improves risk prediction, and tools like the Kidney Failure Risk Equation support clinical decision-making. Management includes blood pressure control, use of ACE inhibitors or ARBs (especially in albuminuria), and adding agents like SGLT2 inhibitors, GLP-1 receptor agonists, or statins when appropriate. The guideline underscores individualized care, multidisciplinary teams, and patient engagement through shared decision-making.
View ArticleJAMA Psychiatry.
Does adding simvastatin to escitalopram improve depressive symptoms in patients with major depression and obesity?
Clinical Bottom Line: In adults with major depressive disorder and obesity, adding simvastatin to escitalopram did not significantly improve depressive symptoms over 12 weeks compared with escitalopram alone. While simvastatin improved lipid profiles and reduced inflammation markers, it did not provide additional mental health benefits.
Summary: This multicenter, double-blind randomized clinical trial evaluated the efficacy of simvastatin (40 mg daily) added to escitalopram in 160 adults with major depression and obesity. After 12 weeks, there was no significant difference in depressive symptom improvement between the simvastatin and placebo groups. Secondary mental health outcomes also showed no benefit. However, simvastatin significantly reduced LDL cholesterol, total cholesterol, and C-reactive protein, indicating cardiovascular benefit. Overall, simvastatin may improve metabolic health but does not enhance antidepressant efficacy in this population.
View ArticleAmerican College of Obstetricians and Gynecologists
What are the best practices for pain management during in-office uterine and cervical procedures?
Clinical Bottom Line: Pain during in-office gynecologic procedures is frequently underestimated. A range of pain-management strategies should be discussed with patients, tailored to individual needs, and guided by shared decision-making. Local anesthetics and NSAIDs are supported for certain procedures, while evidence for other interventions remains limited or mixed. Clinicians must be mindful of patient history, trauma, and systemic biases when managing pain.
Summary: This consensus statement highlights the need for individualized and inclusive pain management during common in-office gynecologic procedures. Local anesthesia is effective for IUD insertion, hysteroscopy, and cervical procedures, while NSAIDs are helpful for endometrial biopsy and uterine aspiration. Misoprostol may reduce pain during hysteroscopy but causes significant side effects. Evidence is limited for oral opioids or anxiolytics. Health care professionals should engage in shared decision-making, acknowledge disparities in pain perception and treatment, and consider trauma histories, age, gender diversity, and cultural context in their approach.
View ArticleHealthcare Improvement Scotland
Are digital diabetes prevention programmes effective and cost-efficient in reducing the risk of type 2 diabetes in high-risk populations?
Clinical Bottom Line: Digital diabetes prevention programmes (DDPPs) are clinically effective in reducing HbA1c, weight, and progression to type 2 diabetes in people with non-diabetic hyperglycaemia (NDH). They are at least as effective as in-person interventions and show promise for wider population reach and equitable access. While robust UK-specific cost-effectiveness evidence is limited, modelling suggests DDPPs are likely to be cost-effective or cost-saving in the long term, particularly if completion rates are high and programme costs are controlled.
Summary: Digital diabetes prevention programmes (DDPPs) are as effective as in-person programmes at reducing weight, lowering HbA1c, and preventing progression to type 2 diabetes in high-risk individuals. They can reach a broader population, including younger people and those in rural or underserved areas, and are particularly valuable for individuals less likely to engage with traditional services. Engagement is improved by support from health coaches and social networks. While UK-specific economic evaluations of DDPPs are limited, modelling suggests they are likely to be cost-effective or cost-saving, particularly if completion rates are high. A national rollout in Scotland could reduce healthcare costs and health inequalities, though attention to implementation, engagement, and equity will be essential.
View ArticleAMA Netw Open.
Does taking antihypertensive medication at bedtime improve cardiovascular outcomes in frail older adults compared to morning dosing?
Clinical Bottom Line: In frail older adults, switching antihypertensive medications to bedtime does not reduce all-cause death or major cardiovascular events compared to usual (primarily morning) dosing. Bedtime dosing may modestly reduce unplanned hospital or emergency visits, but does not impact other clinical outcomes or adverse events.
Summary: The BedMed-Frail randomized clinical trial evaluated whether bedtime versus morning administration of once-daily antihypertensive medications affects cardiovascular outcomes in frail older adults in long-term care settings. Among 776 participants (median age 88), no significant difference was found in the primary outcome of all-cause death or major cardiovascular events. Bedtime dosing slightly reduced unplanned hospital or emergency department visits but had no impact on ischemic or hypotensive adverse events. These findings suggest administration time has minimal effect on outcomes in this population.
View ArticleSociety for Maternal-Fetal Medicine
Can standardised education and timely primary care transition improve long-term outcomes in patients with hypertensive disorders of pregnancy?
Clinical Bottom Line: Hypertensive disorders of pregnancy (HDP) significantly increase long-term cardiovascular risk, yet postpartum education and care transition are inconsistently provided. The Society for Maternal-Fetal Medicine recommends two quality metrics to address this gap: one ensuring predischarge patient education on long-term HDP risks and the other measuring successful transition to primary care within 12 months. Implementation of these metrics can support early intervention and improve long-term outcomes but requires systemic changes in education, follow-up coordination, and healthcare access.
Summary: This SMFM special statement highlights the need for structured postpartum care for individuals with hypertensive disorders of pregnancy, a group at high risk for future cardiovascular disease. Two proposed quality metrics aim to close care gaps: (1) education before hospital discharge about long-term risks and the need for follow-up, and (2) documented follow-up with a primary care provider within 12 months. Current performance is poor, with under 50% receiving follow-up. Barriers include limited provider awareness, poor communication between obstetric and primary care providers, insurance limitations, and social determinants of health. The statement calls for widespread adoption of these metrics, improved patient education protocols, and systems to support timely and equitable care transitions.
View ArticleJAMA Netw Open .
Does adding parenting training to family-based behavioral treatment improve weight loss outcomes in children with obesity?
Clinical Bottom Line: Adding intensive parenting training to family-based behavioral treatment (FBT) for children with obesity does not significantly improve average weight outcomes compared to FBT alone. However, it increases the proportion of children achieving clinically meaningful weight loss, suggesting some added benefit for certain families.
Summary: This randomized clinical trial assessed whether supplementing standard family-based behavioral treatment (FBT) with parenting training (PT) improves weight loss in children aged 7–12 with overweight or obesity. Both treatment arms led to significant reductions in BMI z scores and BMIp95 at 6 months and follow-up. While overall weight changes did not differ significantly between groups, a higher proportion of children in the FBT plus PT group achieved clinically meaningful weight loss (≥0.20 reduction in BMI z score). The interventions were well tolerated with similar dropout rates. These findings support the potential value of parenting skills training for enhancing individual treatment response.
View ArticleDiabetes Obes Metab.
Are oral hypoglycaemic drugs effective and safe as add-on therapy to insulin in patients with type 1 diabetes mellitus?
Clinical Bottom Line: Oral hypoglycaemic drugs (OHDs) used alongside insulin in type 1 diabetes modestly improve glycaemic control and reduce insulin requirements, without increasing the risk of hypoglycaemia. However, they significantly raise the risk of adverse events, including diabetic ketoacidosis and infections, necessitating careful patient selection and monitoring.
Summary: This systematic review and meta-analysis of 51 randomized trials involving 8664 patients found that adding oral hypoglycaemic drugs to insulin therapy in type 1 diabetes led to small but statistically significant improvements in HbA1c, fasting and postprandial glucose, insulin dose, and body weight. Importantly, this approach did not increase hypoglycaemia risk. However, it was associated with a higher incidence of serious adverse events—especially ketoacidosis, genital infections, and gastrointestinal side effects. Subgroup analyses suggested adults benefit more than children in terms of glucose reduction. While OHDs may benefit selected patients, safety concerns require individualized risk–benefit evaluation.
View ArticleCMAJ.
How should primary-care clinicians in Canada diagnose and treat hypertension in adults, according to the 2025 Hypertension Canada guideline?
Clinical Bottom Line: For Canadian adults, hypertension is defined as ≥ 130/80 mm Hg (confirmed with standardized measurements). Treat to < 130 mm Hg systolic using lifestyle measures plus a step-wise, evidence-based drug algorithm (first-line: thiazide-type diuretic, ACE inhibitor, ARB, or CCB; rapidly combine agents as needed). Rigorous diagnosis and aggressive, algorithm-driven treatment in primary care are expected to reverse declining control rates and cut cardiovascular events and mortality.
Summary: This Canadian guideline defines hypertension as ≥130/80 mm Hg and recommends targeting systolic BP <130 mm Hg. It promotes accurate diagnosis using standardized measurements and a stepwise treatment approach starting with lifestyle changes and first-line medications. Designed for primary care, the guideline aims to reverse declining hypertension control and reduce cardiovascular risk.
View Article
